Veradermics Phase 3 Trial Results for Oral Minoxidil Tablet VDPHL01
American pharmaceutical company Veradermics announced Phase 3 clinical trial results on October 19, 2026, for VDPHL01, an investigational extended-release oral minoxidil tablet designed to treat common hair loss in men. The randomized, double-blind, placebo-controlled study, registered under NCT06972264, evaluated 536 male participants with mild to moderate hair loss over a six-month treatment period, according to the company’s press release.
Trial Design and Dosage Groups in Study 304
Study 304 divided participants into three distinct cohorts to test efficacy and safety without patient or physician bias. One group received a single daily tablet containing 8.5 milligrams of the active ingredient, a second group took two tablets daily, and a control group received an identical placebo containing no active medication. The company reported that neither the patients nor the treating physicians knew which treatment each participant received throughout the duration of the trial.
Hair Density and Subjective Improvement Metrics
Participants taking a single 8.5 mg dose experienced a mean increase of 28.6 thick hairs per square centimeter, while those taking two daily doses gained 36.4 thick hairs per square centimeter. After subtracting a placebo group increase of 6.6 thick hairs per square centimeter, the net gain measured approximately 22 hairs for the single dose and 30 hairs for the double dose. Subjective self-assessments showed that 78.8 percent of single-dose users and 85 percent of double-dose users noticed an overall improvement, compared to 35.3 percent of participants in the placebo group.
Reported Adverse Events and Side Effects
The trial recorded no serious adverse events or significant heart-related complications linked to the treatment. Mild to moderate side effects included peripheral edema, or ankle swelling, which affected 2.8 percent of single-dose users and 4.5 percent of double-dose users, compared to 0.6 percent of the placebo group.
Pending 12-Month Data and Upcoming Regulatory Steps
Veradermics has not yet published the trial results in a peer-reviewed journal or provided a specific date for submitting an application to the U.S. Food and Drug Administration. The company awaits 12-month data from a separate investigation, Study 302, which follows 519 men. Meanwhile, a parallel clinical trial evaluating the 4.5 mg dose in 556 female participants is expected to yield initial findings in the first half of 2027.
Frequently Asked Questions About the VDPHL01 Trial
When will the FDA decide on the approval of VDPHL01?
Veradermics has not released a timeline for submitting its new drug application to the U.S. Food and Drug Administration. The regulatory review process will begin only after the company formally files its application following the completion of ongoing trials.
How does VDPHL01 differ from standard topical minoxidil?
Topical minoxidil is a liquid or foam applied directly to the scalp, originally commercialized as Rogaine in 1988 following its discovery as a blood pressure medication. VDPHL01 is an oral tablet utilizing an extended-release mechanism to deliver the active pharmaceutical ingredient gradually.
Are there clinical trial results available for women?
The current Phase 3 dataset covers exclusively male participants with mild to moderate hair loss. A separate clinical trial evaluating a 4.5 mg dose in 556 female participants is underway, with initial results anticipated during the first half of 2027.
Keep reading